Abstract LB-166: Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Sweeney, Christopher J
  • Zukotynski, Katherine
  • Wang, Xiaodong
  • Wick, Andrew
  • Fredericks, Amanda
  • Lam, Bon
  • Kantoff, Philip

publication date

  • April 15, 2013